ConductScience.org, home

Paper36225

Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients.

Hess AD and 2 others. Cancer Res, 1979. Cited by 46 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Papers, record 36225. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36225

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients.
PubMed
Journal
Cancer Res
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
1.59
iCite
Revised in PubMed
2004-11-17
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hess ADA D
2Gall SAS A
3Dawson JRJ R

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ascitic FluidMajor topic
LymphocytesMajor topic
Ovarian NeoplasmsMajor topic
Cell Line
Dose-Response Relationship, Immunologic
Exudates and Transudates
Female
Humans
Hydrogen-Ion Concentration
Lymphocyte Activation
Molecular Weight
Temperature
Time Factors

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
35396222Ovarian Cancer Ascites Inhibits Transcriptional Activation of NK Cells Partly through CA125.J Immunol2022https://conductscience.org/library/papers/35396222PubMed
7138773Cellular immune function study in an ovarian cancer-prone kindred.Br J Cancer1982https://conductscience.org/library/papers/7138773PubMed
6961950Regulation of human natural killing by levamisole.Cancer Immunol Immunother1982https://conductscience.org/library/papers/6961950PubMed
6332671Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6332671PubMed
6177328Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells.Br J Cancer1982https://conductscience.org/library/papers/6177328PubMed
3030577Immunobiology of complete molar pregnancy and gestational trophoblastic tumor.Cancer Metastasis Rev1986https://conductscience.org/library/papers/3030577PubMed
1998971Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.Cancer Immunol Immunother1991https://conductscience.org/library/papers/1998971PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36225

GET https://conductscience.org/api/papers/v1/36225/authors